Dirk Schadendorf

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

2021 | 1. lékařská fakulta

Publikace